drugset / Trial / NCT06315426

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

NCT06315426 ↗

Phase 2 Active not recruiting 240 enrolled Genrix (Shanghai) Biopharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

Timeline

Start
2024-03-24
Primary completion
2025-05
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject GR1802 Monoclonal antibody — —